CAR T
Showing of 6 results
Research Team from Wesley Center for Immunotherapy at UH Seidman Cancer Center Awarded Top Scoring Abstract Award at the 2025 International Society for Cell and Gene Therapy Annual Meeting
Dr. David Wald and his colleagues selected for their abstract "Development and Clinical Validation of a Less Than One Day CAR T-cell Therapy Manufacturing Process".
Phase 1 BAFF CAR T Clinical Trial for Patients with Relapsed and Refractory Multiple Myeloma Underway at UH Seidman Cancer Center
Study is being done through an agreement between UH and Luminary Therapeutics.
Cleveland Innovation District Partners Exceeding Many Targets Set by State and JobsOhio
25 examples of progress showcase the impact of successful collaboration.
Team Led by University Hospitals Seidman Cancer Center Researcher Develops and Validates Three-in-One CAR T Therapy
Research detailed in the journal Nature Communications shows therapeutic potential of BAFF CART for treating multiple B cell cancers, using mouse models with high effectiveness and minimum side effects
New Clinical Trials from University Hospitals Seidman Cancer Center to Begin with Human Protein
Follows successful on-site approach to producing and using anti-CD19 CAR T-Cells against B-cell malignancies; significant findings published in the journal Nature Communications this month.
University Hospitals First in Ohio to Treat Patients with Two FDA-Approved CAR T Cancer Therapies
Latest immunotherapies target multiple myeloma and diffuse large B-cell lymphoma.